Unraveling the role of gut microbiome in predicting adverse events in neoadjuvant therapy for rectal cancer
Jingxin Ma Shengbo Sun Xin Cheng Cong Meng Hanzheng Zhao Wentao Fu Yan Gao Liyan Ma Zhengyang Yang Hongwei Yao Jianrong Su a Department of Clinical Laboratory,Beijing Friendship Hospital,Capital Medical University,Beijing,People's Republic of Chinab School of Basic Medical Sciences,Capital Medical University,Beijing,People's Republic of Chinac Department of General Surgery,Beijing Friendship Hospital,Capital Medical University,National Clinical Research Center of Digestive Diseases,Beijing,People's Republic of ChinaZhengyang Yang He is an attending physician at Capital Medical University affiliated Beijing Friendship Hospital. His main research direction is the comprehensive treatment of gastrointestinal malignant tumors. He has published many articles in international high-quality journals such as Signal Transduction and Targeted Therapy,Med,Trends Cancer,Biomaterials,and Chemical Engineering Journal.Hongwei Yao He is the director of the Department of Gastrointestinal Surgery at Capital Medical University affiliated Beijing Friendship Hospital. He is also a member of the Colorectal Surgery Group under the Surgical Branch of the Chinese Medical Association. His primary focus is on gastrointestinal cancer surgery and has published articles in Signal Transduction and Targeted Therapy,Gastroenterology,and Biomaterials.Jianrong Su She is currently a professor of Clinical Laboratory Center of Capital Medical University affiliated Beijing Friendship Hospital and deputy director of the Department of Clinical Laboratory Diagnosis of Capital Medical University. She is also an executive member of Clinical Microbiology and Infection Branch of China Association for the Promotion of International Exchange of Healthcare. Her main research interests are cancer therapy and intestinal microbiome. She serves as an invited editorial board member of Chinese Medical Journal,Chinese Journal of Laboratory Medicine,and Journal of Laboratory Diagnosis and Automation. She has published numerous articles in international journals,including Med,International Journal of Antimicrobial Agents,and Journal of Medical Virology.
DOI: https://doi.org/10.1080/21645515.2024.2430087
2024-12-04
Human Vaccines & Immunotherapeutics
Abstract:Some patients may develop adverse events during neoadjuvant chemoradiotherapy combined with immunotherapy, influencing response rates. The roles of intestinal microbiome and its metabolites in therapeutic adverse events remain unclear. We collected baseline fecal samples from 21 patients with adverse events (AE group) and 11 patients without adverse events (Non-AE group). Their microbiota and metabolome were characterized using metagenomic shotgun sequencing and untargeted metabolomics. At the species level, the gut microbiota in the Non-AE group exhibits significantly higher abundance of Clostridium sp . Alistipes sp . and lower abundance of Lachnoclostridium sp . Weissella cibaria , Weissella confusa , compared to the AE group ( p < .05). A total of 58 discriminative metabolites were identified between groups. Beta-alanine metabolism was scattered. Boc-beta-cyano-L-alanine and CoQ9 were significantly increased in patients without adverse events, while linoleic acid increased in patients with adverse events. The increased Alistipes sp . in the Non-AE group was positively correlated with Boc-beta-cyano-L-alanine and negatively correlated with linoleic acid ( p < .05). We constructed a combined microbiome-metabolite model to distinguish Non-AE and AE patients with an AUC of 0.963 via the random forest algorithm. Our findings provided a novel insight into the interplay of multispecies microbial cluster and metabolites of rectal patients with adverse events in neoadjuvant chemoradiotherapy combined with immunotherapy. These microbiota and metabolites deserve further investigations to reveal their roles in adverse events, providing clues for better treatment scenarios. Trial registration number : ClinicalTrials.gov identifier: NCT05368051
immunology,biotechnology & applied microbiology